Unit
Rheumatologie
RHEUMA · Dept. I
Sanofi GCA EFC15068
Jul 4, 2019A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
Clinical Studies - Jul 4, 2019 - Jul 8, 2020
Aborted
Project leader: Rubbert-Roth Andrea
Members: Neumann Thomas, Bartz-Batliner Mira, Peischl Riana, Sasselli Clelia
Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Apr 2, 2019Giant Cell Arteritis: Phase 3 Safety and Efficacy Study of Upadacitinib in Subjects with Giant Cell Arteritis
Clinical Studies - Apr 2, 2019 - Dec 31, 2024
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas, Peischl Riana, Sasselli Clelia
Lilly JAHZ A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib
Feb 28, 2019A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with systemic lupus erythematosus (SLE).
Clinical Studies - Feb 28, 2019 - Feb 28, 2022
Completed
Project leader: Rubbert-Roth Andrea
Members: Neumann Thomas, Bartz-Batliner Mira, Hutz Carina Liane, Peischl Riana, Sasselli Clelia
CORBUS: Lenabasum bei diffuser systemischer Sklerose
Sep 25, 2018A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Clinical Studies - Sep 25, 2018 - Sep 27, 2021
Aborted
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas
Abbvie M15-925: A Phase 3, Randomized, Active-Controlled,
Aug 15, 2018
Clinical Studies - Aug 15, 2018 - Aug 16, 2024
Completed
Project leader: Hutz Carina Liane, Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Neumann Thomas
Skippain
Jan 29, 2018SKIPPAIN (Speed of onset of SecuKinumab-Induced relief from Pain in Patients with AxIal SpoNdyloarthritis) A 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of secukinumab in controlling sp...
Clinical Studies - Jan 29, 2018 - Jun 29, 2019
Completed
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Forrer Silvia, Bartz-Batliner Mira
Lilly RHCF SPIRIT
Oct 16, 2017A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive
Clinical Studies - Oct 16, 2017 - Oct 24, 2021
Completed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Forrer Silvia, Hutz Carina Liane, Neumann Thomas
Abbvie M15-572 Phase 3 PsA mit inadäquater Response auf bDMARD
Oct 2, 2017A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumat...
Clinical Studies - Oct 2, 2017 - Oct 3, 2024
Automatically Closed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Neumann Thomas
Finch 302 Gilead
May 24, 2017A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Sub...
Clinical Studies - May 24, 2017 - Sep 26, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
CCX_Chemocentryx CL010 CCX168 (Avacopan)
May 15, 2017A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cycloph...
Clinical Studies - May 15, 2017 - May 31, 2021
Completed
Project leader: Neumann Thomas
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Rubbert-Roth Andrea
BIOBIO
Feb 14, 2017A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients with Rheumatoid Arthritis to a Specific Biologic Mode of Action
Clinical Studies - Feb 14, 2017 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Hutz Carina Liane, Bartz-Batliner Mira, Schmidig Kathrin
Maximise
Dec 5, 2016MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52-week study to assess the efficacy and safety of secukinumab 150 mg or 300 mg s.c. in patients with activ...
Clinical Studies - Dec 5, 2016 - Sep 13, 2019
Completed
Project leader: Rubbert-Roth Andrea
Members: Bartz-Batliner Mira, Hutz Carina Liane, Forrer Silvia
BI1199.214 Senscis
Aug 9, 2016A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD). A trial to compare nintedanib...
Clinical Studies - Aug 9, 2016 - Sep 8, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
BAY16277 RISE
May 13, 2016A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) Evaluierung der Wirksamkeit und Sicherheit einer 52-wöchigen Behandlung m...
Clinical Studies - May 13, 2016 - Apr 28, 2019
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
SpA: AIN 457F2320
Aug 5, 2015A randomized, double-blind, placebo-controlled, phase III multicenter study of subcutaneous secukinumab (150 mg) with and without a subcutaneous loading regimen to assess efficacy, safety, and tolerability up to 2 years in patients with active ankylo...
Clinical Studies - Aug 5, 2015 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin
aSCore: LONG-TERM EXPERIENCE WITH ABATACEPT SC IN ROUTINE CLINICAL
May 6, 2015STUDY DESIGN Overview of Study Design This is a non-interventional, multicenter, study consisting of 2 prospective cohorts of patients diagnosed with moderate to severe active RA and initiated/treated with abatacept SC. In some countries, patients ca...
Clinical Studies - May 6, 2015 - Oct 6, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Schmidig Kathrin, Bartz-Batliner Mira, Hutz Carina Liane
Evaluation and verification of serological activity markers in systemic lupus erythematosus
Apr 1, 2015Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease. So far, there is little evidence for the existence of specific biologic markers reliably indicating clinical activity and a rather wide panel of unspecific markers indica...
Fundamental Research - Apr 1, 2015 - Mar 31, 2018
Automatically Closed
Project leader: von Kempis Johannes
Members: Schmiedeberg Kristin
Fibromyalgie: A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated with Fibromyalgia
Nov 16, 2014This is a randomized, double-blind, double-dummy, placebo- and active controlled, multi-center study of DS-5565 in subjects with pain associated with FM. Eligible subjects will be randomized in the ratio of 1:1:1:1 to receive 13 weeks of treatment wi...
Clinical Studies - Nov 16, 2014 - May 31, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia
M13-375SpoA: A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of
Sep 9, 2014Das Ziel dieser Studie ist es, die Wirksamkeit und Sicherheit der Fortsetzung vs. des Abbruchs der Therapie mit Adalimumab 40 mg, das jede zweite Woche subkutan verabreicht wird, in Bezug auf die Aufrechterhaltung der Remission bei Probanden mit nich...
Clinical Studies - Sep 9, 2014 - Apr 7, 2017
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia
PsoA: A phase III, randomized, double-blind, placebo-controlled multicenter
Aug 20, 2014Study to demonstrate the efficacy at 24 weeks and to assess the long term efficacy, safety and tolerability of secukinumab in Active Psoriatic Arthritis
Clinical Studies - Aug 20, 2014 - Aug 16, 2018
Completed
Project leader: Müller Rüdiger
Members: Forrer Silvia, Bartz-Batliner Mira, Hutz Carina Liane, Schmidig Kathrin